NETesting is intended to aid in the identification of neuroendocrine tumor disease activity. This is defined as the calculated risk of highly active disease as measured by an algorithm based on a combination of gene expression data and clinical parameters.
The NETest is a MultiAnalyte with Algorithm Analyses (MAAA) and comprises a panel of 51 target gene assays, that are both informative about the biology of the tumor as well as can be used for normalization and quality control. The results from the gene expression data are used in the calculation of the NETest score – a percentage ranging from 0 to 100%. The higher the score, the higher the risk of tumor activity at the time of testing.
The NETest is performed at the CLIA-certified clinical laboratory at Wren Laboratories in Branford, Connecticut. A requisition is required for the NETest. Please provide this to the patient to be included with the blood sample.
The NETest has been used over 2,000 times in 15 centers in the United States.
Any questions regarding ordering the test, please email: firstname.lastname@example.org